CRISPR-Edited Donor Stem Cells Enable Safer CD33-Targeted Therapy for Aggressive Blood Cancers

Trial Overview: In a phase 1–2 trial, CRISPR was used to delete CD33 from donor hematopoietic stem cells (trem-cel) before allogeneic transplant in 30 adults with high-risk AML or MDS. Key Findings: All patient...



























